Key result
An anti-CaMBD antibody prevented ET-1-triggered intracellular events and the development of hypertrophy in cultured neonatal cardiomyocytes.
Why the study?
Does an anti-CaMBD antibody prevent ET-1 induced hypertrophy in neonatal cardiomyocytes?
Does an anti-CaMBD antibody prevent ET-1 induced hypertrophy in neonatal cardiomyocytes?
The aberrant formation of the activation link between CaMBD and CaMLD of the ryanodine receptor is a key step in cardiomyocyte hypertrophy, which can be prevented by targeting this interaction.
Findings in neonatal cardiomyocytes do not support clinical use; leaves open CaMBD-CaMLD targeting for hypertrophy in vivo.
We have shown previously that the inter-domain interaction between the two domains of RyR (ryanodine receptor), CaMBD [CaM (calmodulin)-binding domain] and CaMLD (CaM-like domain), activates the Ca(2+) channel, and this process is called activation-link formation [Gangopadhyay and Ikemoto (2008) Biochem. J. 411, 415-423]. Thus CaM that is bound to CaMBD is expected to interfere the activation-link formation, thereby stabilizing the closed state of the channel under normal conditions. In the present paper, we report that, upon stimulation of neonatal cardiomyocytes with the pro-hypertrophy agonist ET-1 (endothelin-1), CaM dissociates from the RyR, which induces a series of intracellular events: increased frequency of Ca(2+) transients, translocation of the signalling molecules CaM, CaMKII (CaM kinase II) and the transcription factor NFAT (nuclear factor of activated T-cells) to the nucleus. These events then lead to the development of hypertrophy. Importantly, an anti-CaMBD antibody that interferes with activation-link formation prevented all of these intracellular events triggered by ET-1 and prevented the development of hypertrophy. These results indicate that the aberrant formation of the activation link between CaMBD and CaMLD of RyR is a key step in the development of hypertrophy in cultured cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Gangopadhyay et al. (2011) studied Hypertrophy in cultured cardiomyocytes. anti-CaMBD antibody was evaluated on Development of hypertrophy and intracellular events triggered by ET-1. An anti-CaMBD antibody prevented ET-1-triggered intracellular events and the development of hypertrophy in cultured neonatal cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: